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ABSTRACT: Siderophores are iron chelators secreted by
bacteria to scavenge iron(III) from their surrounding environ-
ment. They possess their own internalization pathway that is
suﬃciently unselective to be hijacked, making them suitable for
Trojan Horse strategy applications. A commercially available
siderophore, deferoxamine B (DFO), was derivatized at the
primary amine with carboxylic acids bearing diﬀerent ligands to
aﬀord mono- and bidentate complexes with ruthenium as well as
a RAPTA-like complex in which DFO is tethered to the
coordinated arene ring. These compounds were tested for
antibacterial activity against key ESKAPE pathogens, and
antiproliferative studies against healthy (HEK-293) and tumoral
(A2780) human cells were performed. Some of the complexes
displayed interesting dual anticancer and antibacterial properties.
Combining these two properties within a single compound is desirable as patients treated for cancer have a weakened ability for
ﬁghting infections.
■ INTRODUCTION
Since the discovery of penicillin in 1928,1 a tremendous
number of antimicrobial drugs have been developed targeting
bacteria (antibacterial), fungi (antifungal), viruses (antiviral),
and parasites (antiparasitic). As a consequence, many common
yet fatal illnesses such as pneumonia and tuberculosis have
become less deadly. Infections were, for a time, no longer an
ever present risk and the dangers linked to surgery or childbirth
were drastically reduced. However, due to the intensive
worldwide use of antibiotics, especially in agriculture, bacteria
and other pathogens have evolved to overcome the eﬀect of
these drugs. Antimicrobial resistance (AMR) is becoming
increasingly problematic as the discovery of new antibiotic
formats has slowed, and is now an issue of global
importance.2−5 With infections and infectious diseases
remaining one of the major causes of death worldwide,6 and
the emergence of antibacterial resistance, the development of
novel classes of antibacterial drugs is of the utmost importance.
Ruthenium(III) and ruthenium(II) drugs are prominent
families of anticancer agents, developed in the quest to
overcome platinum-based resistance.7 At the forefront are
NAMI-A,8 KP1019,9 and NKP-1339,10 showing promising
results in preclinical and phase I and I/II clinical trials.
Ruthenium(II)−arene complexes such as RAPTA ([Ru(η6-
arene)X2(PTA)], PTA = 1,3,5-triaza-7-phosphaadamantane)
11
or RAED (([Ru(η6-arene)(en)Cl]+, en = ethylenediamine)12
show a wide range of promising anticancer properties.13−15
Interestingly, RAPTA-C, arene = p-cymene, has also been
investigated as a potential antimicrobial agent and displayed
activity against diﬀerent strains of bacteria.16 Ruthenium(II)−
arene complexes represent an interesting platform that can be
easily structurally modiﬁed, and several clinical drugs such as
kinase inhibitor staurosporine,17 glutathione-S-transferase in-
hibitor ethacrynic acid,18 antifungal agents,19 or antibacterial
quinolones20,21 have been coupled to them, either to augment
their anticancer activity or to have dual-functioning drug
candidates, being both antibacterial and anticancer agents.20,21
Coupling these two therapeutic eﬀects is desirable in the clinics
where patients treated for cancer often show weakened ability
to ﬁght infections.22
Iron is an essential element for almost all organisms (animals,
plants, and micro-organisms), being involved in electron
transport and metabolic processes from photosynthesis to
DNA biosynthesis.23 This involvement in so many biological
reactions makes it a vital element for the survival of living
organisms. While animals can source iron from food, plants and
microorganisms need to obtain it from their surrounding
environment. The most common strategy is the use of ferric
ion chelators as solubilizing agents.24 This is achieved through
the secretion of siderophores (literally “iron carriers”). These
low molecular weight compounds (<1000 Da) possess an
extremely high aﬃnity for the Fe3+ ion.25 Siderophores are
secreted by bacteria in response to an iron restriction to
scavenge any Fe3+ that can be found in the surrounding
environment. Siderophores usually form hexadentate octahe-
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dral complexes with the ferric ion, coordinating through oxygen
atoms of hydroxamates, catecholates, a-hydroxycarboxylates or
their combination.26 Despite being selective for ferrisider-
ophores, this transport system is unselective enough to induce
internalization of exogenous siderophores produced by other
bacteria, referred to as xeno-siderophores.27,28 Siderophores are
vital for bacteria pathogenicity, not only through iron(III)
binding.29
Reversing the idea of using antibacterial drugs in tumor cells,
a Trojan Horse strategy30−35 can be applied to deliver
anticancer compounds such as ruthenium(II)−arene complexes
inside bacteria. Such a strategy takes advantage of the iron-
uptake mechanism of both Gram-positive and Gram-negative
bacteria36 to deliver antibiotic moieties directly to the
cytoplasm to circumvent membrane-mediated AMR.37 The
Trojan Horse strategy takes inspiration from the naturally
occurring sideromycins,38 antibiotics that are covalently linked
to siderophores. Based on the study of these sideromycins and
their potential, the rational design of synthetic siderophore-
drug conjugates was developed, taking advantage of the ability
of bacteria to internalize siderophore derivatives.30,32,39−41
Used in iron-chelation therapy to treat iron overload,42
deferoxamine B (DFO, brand name Desferal) is the only
commercially available clinically approved siderophore that is
available on a gram scale, making it an interesting candidate for
Trojan Horse applications. Several nonferric complexes of this
siderophore have been reported. Al,43 Cr,44 and radioactive
[55Fe]45 derivatives were studied to investigate the coordination
chemistry of this siderophore and the mechanism of
ferrisiderophore uptake. DFO and other iron chelators have
also been investigated as antimalarial agents acting by iron
sequestration.46−48 Therapeutically relevant studies have been
performed on a gallium−DFO complex, which showed potent
antibacterial properties against antibiotic-resistant P. aerugino-
sa.49 The primary amine of DFO does not participate in the
binding to iron and can therefore be functionalized without
drastically interfering with the binding. Several synthetic
conjugates of DFO and its analogs with antibiotic moieties
have also been synthesized and showed antibacterial activity
(Figure 1), although usually lower than the drug alone.33,50,51
Derivatives of DFO with ﬂuorophores have also been
synthesized to study the mechanism of action of such Trojan
Horse drugs.52 Nonantibacterial drugs, such as DNA
intercalators, have also been investigated.53 It was found that
such compounds degrade DNA through redox damage due to
the iron.
Metal-based drugs such as RAPTA complexes have not
previously been used as components of Trojan Horse
antimicrobial drugs, despite the fact that they display some
intrinsic antibacterial properties. Here, we describe the
synthesis of conjugates of DFO with ruthenium(II)−arene
fragments for potential dual antibacterial/anticancer drugs, and
their cytotoxicity studies against human cancerous and healthy
cells, as well as resistant and nonresistant bacteria strains.
Figure 1. General structure and selected examples of deferoxamine B (DFO) derived Trojan Horse antibacterial drugs.
Scheme 1. Synthesis of Ligands 2a−c, and Ruthenium(II) Arene Complexes 3a−c
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■ RESULTS AND DISCUSSION
A series of ruthenium(II)−arene complexes modiﬁed with
DFO, 3a−c, were prepared using the route presented in
Scheme 1. Coupling of carboxylic acids with the primary amine
of DFO was optimized from the adaption of a literature
procedure.54 A solution of carboxylic acid activated by
carbonyldiimidazole (CDI) at 60 °C in dimethylformamide
(DMF) was added dropwise to a solution of DFO and
triethylamine in dimethylsuﬂoxide (DMSO), and the reaction
mixture was stirred at 60 °C and monitored by mass
spectrometry (MS). Completion was reached in less than an
hour for all ligands 2a−c (Scheme 1). After puriﬁcation, they
were all obtained in good yields (77−88%).
The ruthenium(II) complexes 3a−c were prepared in a
single step from 2a−c by reaction with the dichloro(p-
cymene)ruthenium dimer in dry methanol under inert
conditions over 1 h. The RAPTA-type complex 3d was
prepared following a related reported procedure55 using TBTU
(2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium tetra-
ﬂuoroborate) as the coupling agent in the presence of
diisopropylethylamine (DIPEA) in DMSO. Following puriﬁca-
tion, complexes 3a−d were obtained in moderate to good
yields (57−82%).
All compounds were characterized by 1H, 13C{1H}, and
where applicable, 31P NMR spectroscopy, ESI-MS, and
elemental analysis. NMR spectra of 3a and 3b indicate the
presence of several species, most notably for 3b (see Figures
S11 and S12), the two chlorides initially bound to ruthenium
being substituted by two oxygen atoms of DFO. Several
diﬀerent modes of coordination of DFO to the ruthenium
center (through two of its three hydroxyl groups and one
hydroxamate) are possible, hence the presence of several
species. Although the use of protection groups such as an
oxalate moiety could avoid this displacement,55 it was found to
be unnecessary since, upon addition of an equimolar solution of
iron(III) chloride, both 3a and 3b mixtures gave only one
compound with two chlorides bound to the ruthenium(II)
center.
Complex 3a was obtained as one major product and several
minor species. Complexation was assessed by positive ion ESI-
MS and NMR spectroscopy. The aromatic protons of the
pyridyl moiety shift from 8.61 (ortho to the nitrogen) and 7.53
(meta to the nitrogen) to 8.47 and 7.26 ppm, respectively (ΔδH
≈ 0.2 and 0.3 ppm). The singlet corresponding to the
methylene group between the pyridyl and the amide also shifts
to lower frequencies (ΔδH ≈ 0.4 ppm) and becomes a doublet,
indicating the presence of several species. The 13C{1H} NMR
spectrum shows modest changes following complexation to the
ruthenium ion, the pyridyl carbons shifting to lower ppm (ΔδC
≈ 0.8 ppm). Upon addition of FeCl3, the ferrisiderophore
ligand was found to rapidly detach from the ruthenium(II)
center.
Similar changes were observed for 3b, where the aromatic
protons shift to higher frequencies (ΔδH ≈ 0.2 ppm) and
several peaks from the DFO become split. Complexation was
assessed by 31P NMR spectroscopy, where the presence of
several species is shown by several peaks that shifted from
−6.94 ppm (ligand 2b) to 24.0−26.0 ppm, corresponding to
the dichloro form and diﬀerent oxygen-coordinated species at
higher frequencies. Upon addition of an equimolar solution of
iron(III) chloride, only one peak in the 31P NMR spectrum is
observed at 24.9 ppm, corresponding to the dichloro species,
which is also the only product observed by ESI-MS.
Coordination of the ligand to the metal ion is also denoted
by peaks in the 13C{1H} NMR spectrum corresponding to the
quaternary carbon atoms covalently linked to the phosphorus,
which shift to lower frequencies (ΔδC ≈ 1.5 ppm) and larger
coupling constants (Δ1J ≈ 17 and 26 Hz), similar to values
found in literature,56 although the spectrum is complicated by
the presence of several similar species. The amide linking DFO
to the triphenylphosphine moiety also shifts to higher
frequencies (ΔδC = 4.9 ppm).
In contrast to the 2a,b/3a,b pairs, the aromatic protons of
ligand 2c all shift to lower ﬁeld when coordinated to the
ruthenium(II) center. The two doublets corresponding to the
aromatics protons in the ortho position to the nitrogen atoms
shift from 8.65 and 8.54 to 9.48 and 9.38 ppm, respectively
(ΔδH ≈ 0.8 ppm), and their coupling constants increased from
4.9 and 4.8 to 5.7 and 6.0 Hz. The two aromatic singlets shift
from 8.34 and 8.24 to 8.64 and 8.51 ppm (ΔδH ≈ 0.3 ppm),
and the two remaining doublets shift from 7.40 and 7.30 to 7.72
and 7.65 ppm (ΔδH ≈ 0.3 ppm). These last two sets are less
aﬀected than the protons directly ortho to the nitrogen as they
are further from the ruthenium center. Even more remote is the
methylene group between the pyridyl moiety and the ester,
which only shifts by 0.2 ppm (5.22 to 5.40 ppm). Related
changes are also observed in the 13C{1H} NMR spectrum after
coordination with the aromatic carbon atoms shifting to higher
frequencies (ΔδC ≈0.3 to 3.9 ppm).
As the environment of the ruthenium center in 3d is close to
that of its starting material (Scheme 2), coupling with DFO to
aﬀord 3d does not induce drastic changes in the NMR spectra,
except for the addition of new peaks derived from the DFO
moiety. The 1H NMR spectrum presents peaks for both the
DFO moiety and the RAPTA complex with very minor
changes, and the peak in the 31P NMR spectrum corresponding
to the PTA moiety only shifts from −32.2 to −33.3 ppm.
The cytotoxicity of DFO, ligands 2a−c, and ruthenium(II)
complexes 3a−d in the absence or presence of iron(III) was
assessed using the 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-
2H-tetrazolium bromide (MTT) assay57 against human ovarian
carcinoma cell lines (A2780) and human embryonic kidney
(HEK-293) cells (Table 1). The ferrisiderophore species were
obtained by mixing equimolar DMSO solutions of the
corresponding siderophore derivative with FeCl3. Comparison
between this method and the separate synthesis and
puriﬁcation of the ferrisiderophore compounds was performed
and shown to yield similar results. The cytotoxicities of cisplatin
and RAPTA-C were evaluated as positive and negative controls,
respectively. All compounds were predissolved in DMSO
before being immediately diluted into the appropriate cell
culture medium. Stability studies under pseudocell culture
conditions of 100 mM NaCl in H2O and 5% DMSO were
conducted on 3a−d over 72 h. The stability was monitored via
ESI-MS or 1H and 31P NMR spectroscopy. All complexes
showed good stability under these conditions except for 3b in
absence of iron(III), where the arene ligand was displaced (see
Scheme 2. Synthesis of RAPTA Complex Derivative 3d
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Figure S2). Notably, the ferrisiderophore analogue of 3b is
stable under these conditions.
Interestingly, introduction of iron(III) reduces the cytotox-
icity of the compounds, presumably as the three hydroxyl
groups of the siderophore are no longer free. This observation
is apparent for DFO where, upon addition of iron(III), the
cytotoxicity changes from the micromolar range (13 ± 6 and 4
± 2 μM against A2780 and HEK-293, respectively) to inactive
at the maximum dose tested. For potential therapeutic
applications, the ferrisiderophore form would not only help
to avoid unwanted toxicity, but ferrisiderophores are preferen-
tially internalized in bacteria so this form facilitates targeting. In
presence of iron(III), ligand 2c is the only ligand with an
antiproliferative eﬀect against the nontumorigenic HEK-293
cells.
Complexes 3b,c possess moderate cytotoxicity against the
A2780 cell line. In presence of iron(III), 3b displays higher
cytotoxicity against A2780 cells, contrary to the other
compounds (33 ± 2 μM against 109 ± 6 μM in absence of
iron(III)). This may be explained by the decoordination of
DFO from the ruthenium ion, as its aﬃnity for iron(III) is
higher. A 7-fold selectivity toward A2780 cells is observed for
3b in the presence of iron(III), with IC50 values of 33 ± 2 and
>200 μM, which is higher than the 5-fold selectivity of cisplatin
although the overall activity is lower. Despite being cytotoxic to
healthy HEK-293 cells in its iron(III)-free form (IC50 = 23 ± 1
μM), complex 3c is also selective for A2780 cell line in the
presence of iron(III) (91 ± 10 μM versus >200 μM), although
with a lower selectivity than 3b. Due to the structural similarity
with 3b, complex 3a might be expected to follow the same
trend, but the pyridyl ligand 2a was found to dissociate from
the ruthenium center upon addition of iron(III). 3a shows no
cytotoxicity against A2780 and HEK cells (IC50 > 200 μM).
Complex 3d is cytotoxic to both cell lines in its iron(III)-free
form (107 ± 2 and 15 ± 2 μM against A2780 and HEK-293 cell
lines, respectively) but inactive when iron(III) was added.
Contrary to previously described RAPTA complexes such as
RAPTA-C, which possess low cytotoxicities with IC50 values
>200 μM,11 complexes 3a−d are moderately cytotoxic against
human cell lines. As they are structurally similar, cytotoxicity
arises from the functionalization with DFO. Note that other
RAPTA-type compounds modiﬁed with functional bioactive
molecules at the coordinated arene ring are often cyto-
toxic.40,58−60 The activity of both 3b and 3c is in the
micromolar range, with IC50 values 20 to 60 times higher
than cisplatin, albeit comparable to other ruthenium(II)
complexes bearing organic bioactive moieties61,62 or CAP
ligands instead of the PTA moiety,63 but with much higher
selectivity toward cancerous cell lines. The cancer cell
selectivity observed for 3b is higher than cisplatin and similar
to ruthenium(II)-arene compounds bearing perﬂuorinated alkyl
chains64 that show promising in vivo antitumor eﬀects.65
All compounds were tested for activity against four of the key
ESKAPE pathogens (S. aureus, K. pneumoniae, A. baumannii,
and P. aeruginosa),66 as well as E. coli and two fungi, C. albicans
and C. neoformans. Inhibition of bacterial growth at a single
concentration of 20 μM after 18 h of incubation was
determined for 2a−c and 3a−d (Table 2), as well as for
some other ruthenium(II) arene complexes (Table S1). DFO
itself and ligands 2a−c were found to be inactive, some even
promoting bacterial growth, presumably as they help to deliver
iron(III) to the organism. These data show which bacterial
strains and fungi were more susceptible to internalize DFO, as
they grow better in the presence of the siderophore, i.e. E. coli,
P. aeruginosa, and C. neoformans. S. aureus growth was slightly
inhibited by ligands 2a−c, possibly via iron(III) sequestration.
K. pneumoniae, A. baumannii, and C. albicans growth showed no
signiﬁcant change when incubated with the compounds. The
lack of toxicity of the ligand implies that any further activity
found for ruthenium complexes 3a−d emanates from the
ruthenium fragment.
Surprisingly, the same trend was observed for complexes 3b−
d, which all promoted the growth of E. coli and P. aeruginosa in
the presence of iron(III), whereas modest growth inhibition
Table 1. In Vitro Antiproliferative Activity of Compounds
DFO, 2a−c, and 3a−d in the Absence/Presence of 1 equiv of
Iron(III) and Cisplatin and RAPTA-C against Human
Ovarian Carcinoma (A2780) and Human Embryonic Kidney
293 (HEK-293) Cell Lines after 72 h Exposurea
A2780 HEK-293
compd no Fe Fe no Fe Fe
DFO 13 ± 6 >200 4 ± 2 >200
2a >200 >200 >200 >200
2b 21 ± 1 >200 143 ± 23 >200
2c 20 ± 2 >200 19 ± 2 58 ± 4
3a >200 n.a. >200 n.a.
3b 109 ± 6 33 ± 2 >200 >200
3c 48 ± 4 91 ± 10 23 ± 1 >200
3d 107 ± 2 >200 15 ± 2 >200
cisplatin 1.5 ± 0.3 7.3 ± 0.6
RAPTA-C >200 >200
aValues are given as the mean ± standard deviation (μM).
Table 2. Growth Inhibition of Diﬀerent Bacterial Strains and Fungi at 20 μM of DFO, 2a−c, and 3a−d in the Absence or
Presence of 1 equiv of Iron(III) after 18 h Incubationa
S. aureus E. coli K. pneumonia P. aeruginosa A. baumannii C. albicans C. neoformans
compd no Fe Fe no Fe Fe no Fe Fe no Fe Fe no Fe Fe no Fe Fe no Fe Fe
DFO 23 25 15 −8 20 7 7 −24 1 16 9 3 −24 −3
2a 20 25 11 −7 19 5 6 −10 7 15 10 5 −18 6
2b 22 24 18 −17 22 8 0 −27 3 4 6 5 −22 −24
2c 28 20 14 −5 21 8 17 −9 11 14 3 3 −20 6
3a 10 n.a. 28 n.a. 32 n.a. 16 n.a. 34 n.a. 13 n.a. −98 n.a.
3b 16 9 10 −39 36 13 −4 −36 25 23 2 −2 −121 −93
3c 13 7 14 −47 36 17 5 −39 12 7 5 4 −105 −55
3d 10 21 16 −45 41 −9 9 −47 14 −2 8 1 −97 −65
aAll values are given as the percentage of growth inhibition with a ± 10% error.
Organometallics Article
DOI: 10.1021/acs.organomet.7b00885
Organometallics 2018, 37, 915−923
918
(up to 40%) for 3a−d was observed against the same bacterial
strains in absence of iron(III). Presumably competition
between the Trojan Horse complex and bacterial siderophore
takes place.
Additional RAPTA-like complexes were also tested for
antibacterial eﬀects (Table S1). Only one showed signiﬁcant
antibacterial activity against two species (S. aureus and C.
neoformans), a derivative of RAPTA-C bearing a triphenylphos-
phine group instead of the PTA moiety. However, this
compound was previously found to be quite toxic to HEK-
293 cells,56 probably due to its hydrophobicity, and is not
suitable for antibacterial applications. This conﬁrms the
potential of 3b as an antibacterial, since it is structurally similar
in the iron(III)-chelated form. Although ligands 2a−c showed
susceptibility to C. neoformans, all ruthenium complexes
promote the growth of this fungus. For several Trojan Horse
drugs, it was shown that drug release and the use of cleavable
linkers, triggered by phosphatase, esterase,40 or reductase
enzymes,67 might be necessary for more potent activity.68 The
observed relatively low antibacterial activity observed for
complexes 3a−d could be due to the stability of the linkers.
■ CONCLUDING REMARKS
DFO-ligand conjugates 2a−c and DFO-containing ruthenium
complexes 3a−d were synthesized, and their antiproliferative
activity was assessed against human cancerous and non-
cancerous cell lines. Complexes 3b and 3c display good cancer
cell selectively, despite being less active than cisplatin. The
growth inhibitions of several strains of key pathological
bacterial strains by ligands 2a−c, complexes 3a−d, and some
RAPTA-like complexes were also determined. Although only
modest growth inhibition was observed, these compounds are
an order of magnitude more active than ruthenium compounds
modiﬁed with antibacterial/antifungal agents.19,21 Thus, the
modiﬁcation of ruthenium complexes with DFO, allowing it to
be internalized in bacteria, appears to be a more successful
approach, with both cytotoxicities and selectivity against
cancerous cell lines and similar growth inhibition of diﬀerent
bacterial strains at ten times lower concentrations. Further
studies could include the use of other naturally occurring or
synthetic siderophores and an evaluation of the use of cleavable
linkers.
■ EXPERIMENTAL SECTION
Materials. RuCl3·xH2O was purchased from Precious Metals
Online. All other chemicals were purchased from Aldrich, Alfa Aesar,
Acros, Abcam, and TCI chemicals and used without further
puriﬁcation. [Ru(p-cymene)Cl2]2
69 and [Ru(PTA)(μ-oxalato)(3-(4-
methylcyclohexa-1,4-dien-1-yl)propionic acid)]55 were prepared fol-
lowing literature procedures. Dichloromethane (DCM) was dried and
degassed using a PureSolv solvent puriﬁcation system (Innovative
Technology, Inc.). Thin-layer chromatography was conducted on
Merck 60 F254 TLC silica-gel-coated aluminum sheets and veriﬁed by
a UV lamp at 254 nm and KMnO4 staining. The compounds were
puriﬁed via a Varian 971-FP ﬂash chromatography system using
prepackaged silica gels columns (Luknova).
Instrumentation and Methods. 1H (400 MHz), 13C{1H} (101
MHz), and 31P (162 MHz) NMR spectra were recorded on a Bruker
Advance II 400 spectrometer at 298 K. Chemical shifts are reported in
parts per million and referenced to deuterated solvent residual peaks
(CDCl3:
1H, δ 7.26 ppm; 13C{1H}, δ 77.16 ppm. DMSO-d6:
1H, δ
2.50 ppm; 13C{1H}, δ 39.52 ppm). Coupling constants (J) are
reported in hertz (Hz). High-resolution ESI-MS spectra were obtained
on Xevo G2-S QTof (Waters) operated in positive-ion mode.
Elemental analyses were determined on a Thermo Scientiﬁc Flash
2000 organic elemental analyzer. The absorbance of the MTT assay
96-well plates was recorded using a SpectroMax M5e multimode
microplate reader (using SoftMax Pro software, version 6.2.2).
Synthesis. Compound 1. To a suspension of 4-(hydroxymethyl)-
4′-methyl-2,2′-bipyridine (0.50 g, 2.5 mmol, 1.0 equiv) and succinic
anhydride (0.50 g, 5.0 mmol, 2.0 equiv) in dry DCM (15 mL) under
inert atmosphere was added triethylamine (1.3 mL, 12.5 mmol, 5.0
equiv). The reaction mixture was allowed to stir for 72 h, concentrated
in vacuo, washed with Et2O (3 × 15 mL) and hexane (3 × 15 mL),
and dried. The crude product was then puriﬁed by ﬂash column
chromatography (DCM/MeOH gradient) to yield product 1 (0.63 g,
2.1 mmol, 84%) as an oﬀ-white solid. 1H NMR (CDCl3, 400 MHz): δ
8.88 (br, 1 H, CO2H), 8.65 (d, J = 5.3 Hz, 1 H, ArH), 8.55 (d, J = 5.1
Hz, 1 H, ArH), 8.28 (s, 1 H, ArH), 8.19 (s, 1 H, ArH), 7.25 (m, 1 H,
ArH), 7.22 (m, 1 H, ArH), 5.27 (s, 2 H, ArCH2O), 2.79 (m, 2 H,
CH2CH2CO2H), 2.72 (m, 2 H, CH2CH2CO2H), 2.47 (s, 3 H,
ArCH3).
13C{1H} NMR (CDCl3, 101 MHz): δ 175.1 (1 C, CO2H),
172.0 (1 C, CO2CH2), 155.8 (1 C, Ar), 155.5 (1 C, Ar), 149.8 (1 C,
Ar), 149.5 (1 C, Ar), 148.2 (1 C, Ar), 146.6 (1 C, Ar), 125.3 (1 C, Ar),
123.3 (1 C, Ar), 121.9 (1 C, Ar), 120.1 (1 C, Ar), 64.6 (1 C, ArCH2),
30.1 (1 C, CH2CO2H), 29.9 (1 C, CH2CO2CH2), 21.4 (1 C, ArCH3).
HRMS (ESI/Q-TOF) m/z: [M − H]+ calcd for C16H17N2O4
301.1183, found 301.1185. Anal. Calcd for C16H16N2O4: C, 63.99;
H, 5.37; N, 9.33. Found: C, 63.74; H, 5.42; N, 9.43.
General Procedure for the Synthesis of DFO Derivatives 2a−c. A
solution of deferoxamine mesylate (1.0 equiv) and TEA (3.0 equiv) in
DMSO was heated at 60 °C for 30 min. At the same time, a solution of
carboxylic acid (1.2 equiv) and CDI (1.2 equiv) in DMF was heated at
60 °C for 30 min. After 30 min, the solution of activated acid was
added dropwise to the other solution, and the reaction mixture was
stirred for 1 h at 60 °C. The reaction was monitored by mass
spectrometry and after completion, the solvent was evaporated, and
the crude product was puriﬁed by ﬂash column chromatography using
a DCM/MeOH gradient (0−20% over 50 min) as eluent.
Compound 2a. According to the general procedure, 2-(pyridin-4-
yl)acetic acid (0.05 g, 0.4 mmol, 1.2 equiv) and CDI (0.06 g, 0.4
mmol, 1.2 equiv) in DMF (3 mL) reacted with deferoxamine mesylate
(0.20 g, 0.30 mmol, 1.0 equiv) and triethylamine (40 μL, 0.9 mmol,
3.0 equiv) in DMSO (2 mL). The solvent was evaporated, and the
crude product was puriﬁed by ﬂash column chromatography to aﬀord
2a as a yellow powder (0.180 g, 0.2 mmol, 88%). 1H NMR (DMSO,
400 MHz): δ 9.64 (m, 3 H, NH DFO), 8.61 (d, J = 6.2 Hz, 2 H,
NArCH pyridyl), 8.20 (t, J = 5.7 Hz, 1 H, NOH DFO), 7.78 (t, J = 5.6
Hz, 2 H, NOH DFO), 7.53 (d, J = 5.3 Hz, 2 H, ArH pyridyl), 3.59 (s,
2 H, NHC(O)CH2Ar), 3.45 (t, J = 7.2 Hz, 6 H, CH2 DFO), 3.01 (m,
6 H, CH2 DFO), 2.57 (t, J = 7.3 Hz, 4 H, CH2 DFO), 2.31 (residual
mesylate), 2.26 (t, J = 7.4 Hz, 4 H, CH2 DFO), 1.96 (s, 3 H,
CH3C(O) DFO), 1.56−1.14 (m, 18 H, CH2 DFO). 13C{1H} NMR
(DMSO, 101 MHz): δ 172.0 (2 C, C hydroxamic acid DFO), 171.3 (2
C, C amide DFO), 170.1 (1 C, C hydroxamic acid DFO), 168.1 (1 C,
C(O)NDFO), 146.6 (2 C, Ar pyridyl), 125.6 (2 C, Ar pyridyl), 47.1
(DFO), 46.8 (DFO), 41.6 (1 C, CH2Ar), 38.6 (DFO), 38.4 (DFO),
29.9 (DFO), 28.8 (DFO), 28.6 (DFO), 27.6 (DFO), 26.0 (DFO),
23.5 (DFO), 20.4 (DFO). HRMS (ESI/Q-TOF) m/z: [M − H]+
calcd for C32H54N7O9 680.3983, found 680.3978.
Compound 2b. According to the general procedure, 4-
(diphenylphosphino)benzoic acid (0.05 g, 0.2 mmol, 1.2 equiv) and
CDI (0.03 g, 0.2 mmol, 1.2 equiv) in DMF (2 mL) reacted with
deferoxamine mesylate (0.10 g, 0.2 mmol, 1.0 equiv) and triethylamine
(20 μL, 0.5 mmol, 3.0 equiv) in DMSO (1 mL). The solvent was
evaporated, and the crude product was puriﬁed by ﬂash column
chromatography to aﬀord product 2b as an oﬀ-white solid (0.09 g, 0.1
mmol, 74%). 1H NMR (DMSO, 400 MHz): δ 9.63 (m, 3H, NH
DFO), 8.47 (t, J = 5.7 Hz, 1H, NOH DFO), 7.82 (d, J = 7.7 Hz, 2 H,
C(O)ArH), 7.80−7.73 (m, 2 H, NOH DFO), 7.42 (m, 6 H, ArH),
7.28 (m, 6 H, ArH), 7.20 (s, 1 H, ArH), 3.47 (q, J = 6.5 Hz, 6 H, CH2
DFO), 3.23 (q, J = 6.6 Hz, 2 H, CH2 DFO), 3.06−2.92 (m, 4 H, CH2
DFO), 2.58 (t, J = 7.4 Hz, 4 H, CH2 DFO), 2.31 (residual mesylate),
2.27 (t, J = 7.5 Hz, 4 H, CH2 DFO), 1.97 (s, 3 H, CH3C(O) DFO),
1.53−1.15 (m, 22 H, CH2 DFO). 13C{1H} NMR (DMSO, 101 MHz):
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δ 172.0 (2 C, C hydroxamic acid DFO), 171.3 (2 C, C amide DFO),
170.1 (1 C, C hydroxamic acid DFO), 165.7 (1 C, C(O)NDFO), 136.1
(d, 1J = 10.9 Hz, 1 C, P-C(Ar)), 135.0 (d, 1J = 12.4 Hz, 2 C, P-C(Ar)),
133.4 (d, 2J = 19.8 Hz, 2 C, C(Ar)), 132.8 (d, 2J = 19.2 Hz, 4 C,
C(Ar)), 129.2 (1 C, C(O)CAr), 128.9 (d, 3J = 7.0 Hz, 2 C, C(Ar)),
127.3 (d, 3J = 6.6 Hz, 4 C, C(Ar)), 121.0 (2 C, C(Ar)), 47.6 (DFO),
47.2 (DFO), 38.9 (DFO), 30.4 (DFO), 29.3 (DFO), 28.0 (DFO),
26.5 (DFO), 24.0 (DFO), 20.8 (DFO). 31P NMR (DMSO, 162
MHz): δ −6.94. HRMS (ESI/Q-TOF) m/z: [M − Na]+ calcd for
C44H61N6O9PNa 871.4135, found 871.4130.
Compound 2c. According to the general procedure, 4-((4′-methyl-
[2,2′-bipyridin]-4-yl)methoxy)-4-oxobutanoic acid 1 (0.11 g, 0.4
mmol, 1.2 equiv) and CDI (0.06 g, 0.4 mmol, 1.2 equiv) in DMF
(3 mL) reacted with deferoxamine mesylate (0.20 g, 0.3 mmol, 1.0
equiv) and triethylamine (40 μL, 0.9 mmol, 3.0 equiv) in DMSO (2
mL). The solvent was evaporated, and the crude product was puriﬁed
by ﬂash column chromatography to aﬀord 2c as an oﬀ-white solid
(0.22 g, 0.26 mmol, 87%). 1H NMR (DMSO, 400 MHz): δ 9.64 (m, 3
H, NH DFO), 8.65 (d, J = 4.9 Hz, 1 H, ArH), 8.54 (d, J = 4.8 Hz, 1 H,
ArH), 8.34 (s, 1 H, ArH), 8.24 (s, 1 H, ArH), 8.02 (residual CDI),
7.85 (t, J = 5.4 Hz, 1 H, NOH DFO), 7.77 (t, J = 4.8 Hz, 2 H, NOH
DFO), 7.40 (d, J = 5.0 Hz, 1 H, ArH), 7.30 (d, J = 5.0 Hz, 1 H, ArH),
7.19 (residual CDI), 5.22 (s, 2 H, CO2CH2Ar), 3.45 (t, J = 7.0 Hz, 6
H, CH2 DFO), 3.00 (q, J = 6.6 Hz, 6 H, CH2 DFO), 2.64 (t, J = 6.8
Hz, 2 H, NC(O)CH2CH2C(O)), 2.57 (t, J = 7.5 Hz, 4 H, CH2 DFO),
2.42 (s, 3 H, ArCH3), 2.41 (t, J = 6.9 Hz, NC(O)CH2CH2C(O)), 2.31
(residual mesylate), 2.26 (t, J = 7.4 Hz, 4 H, CH2 DFO), 1.96 (s, 3 H,
CH3C(O) DFO), 1.53−1.18 (m, 18 H, CH2 DFO). 13C{1H} NMR
(DMSO, 101 MHz): δ 172.2 (1 C, C(O)NDFO), 172.0 (2 C, C
hydroxamic acid DFO), 171.3 (2 C, C amide DFO), 170.3 (1 C,
CO2CH2Ar), 170.1 (1 C, C hydroxamic acid DFO), 155.5 (1 C, Ar),
154.8 (1 C, Ar), 149.3 (1 C, Ar), 149.1 (1 C, Ar), 148.0 (1 C, Ar),
146.5 (1 C, Ar), 125.1 (1 C, Ar), 122.0 (1 C, Ar), 121.3 (1 C, Ar),
118.5 (1 C, Ar), 63.9 (1 C, ArCH2), 47.1 (DFO), 46.8 (DFO), 38.4
(DFO), 29.9 (DFO), 29.8 (1 C, CH2CONDFO), 29.0 (1 C,
CH2CO2CH2), 28.8 (DFO), 27.6 (DFO), 26.0 (DFO), 23.5 (DFO),
20.7 (1 C, ArCH3), 20.4 (DFO). HRMS (ESI/Q-TOF) m/z: [M −
H]+ calcd for C41H63N8O11 843.4616, found 843.4611.
General Procedure for the Synthesis of Ruthenium
Complexes 3a−c. A solution of ligand 2a−c (1.0 equiv) and
dichloro(p-cymene)ruthenium dimer (1.0 equiv) in methanol was
stirred for 1 h. The reaction was monitored by mass spectrometry, and
after completion, the crude product was puriﬁed.
Compound 3a. According to the general procedure, a solution of
ligand 2a (0.02 g, 0.03 mmol, 1.0 equiv) and dichloro(p-cymene)
ruthenium dimer (0.01 g, 0.03 mmol, 1.0 equiv) in methanol (10 mL)
was stirred for 1 h. After completion, the solvent was evaporated and
the crude product washed with DCM (3 × 10 mL) and acetone (3 ×
10 mL) to aﬀord pure product 3a as an orange powder (0.02 g, 0.02
mmol, 57%). 1H NMR (DMSO, 400 MHz): δ 9.69 (m, 3 H, NH
DFO), 8.47 (d, J = 5.2 Hz, 2 H, NArCH pyridyl), 8.17 (m, 1 H, NOH
DFO), 7.80 (t, J = 5.5 Hz, 2 H, NOH DFO), 7.26 (d, J = 5.2 Hz, 2 H,
ArH pyridyl), 5.82 (d, J = 6.1 Hz, 2H, ArH p-cymene), 5.78 (d, J = 6.2
Hz, 2 H, ArH p-cymene), 3.45 (m, 6 H, CH2 DFO), 3.16 (d, J = 3.6
Hz, 2 H, NHC(O)CH2Ar), 3.01 (m, 6 H, CH2 DFO), 2.83 (sept, J =
6.9 Hz, 1 H, CH(CH3)2), 2.57 (t, J = 7.3 Hz, 4 H, CH2 DFO), 2.31
(residual mesylate), 2.27 (t, J = 7.4 Hz, 4 H, CH2 DFO), 2.09 (s, 3H,
ArCH3) 1.96 (s, 3 H, CH3C(O) DFO), 1.56−1.30 (m, 12 H, CH2
DFO), 1.25−1.16 (m, 6 H, CH2 DFO), 1.19 (d, J = 6.9 Hz, 6 H, iPr).
13C{1H} NMR (DMSO, 101 MHz): δ 172.0 (2 C, C hydroxamic acid
DFO), 171.3 (2 C, C amide DFO), 170.1 (1 C, CH3C(O)N DFO),
168.6 (1 C, C(O)NDFO), 149.3 (1 C, CH2−C(Ar)), 145.4 (2 C, Ar
pyridyl), 124.5 (2 C, Ar pyridyl), 106.4 (1 C, ArCCH3 arene), 100.1 (1
C, ArCiPr arene), 86.4 (2 C, CH arene), 85.5 (2C, CH arene), 48.6
(residual MeOH), 47.1 (DFO), 46.8 (DFO), 41.5 (1 C, CH2Ar), 38.6
(DFO), 38.4 (DFO), 30.2 (1 C, CH(CH3)2) 30.0 (DFO), 28.8
(DFO), 28.7 (DFO), 27.6 (DFO), 26.0 (DFO), 23.5 (DFO), 21.5
(2C, iPr), 20.4 (DFO), 17.9 (1 C, ArCH3)). HRMS (ESI/Q-TOF) m/
z: [M − H]+ calcd for C42H66N7O9Ru 914.3977, found 914.3974.
Compound 3b. According to the general procedure, ligand 2b
(0.05 g, 0.06 mmol, 1.0 equiv) and dichloro(p- cymene)ruthenium
dimer (0.02 g, 0.06 mmol, 1.0 equiv) reacted in methanol (10 mL) for
1 h. After completion, diethyl ether (30 mL) was added, and the
orange precipitate was washed several times with diethyl ether to
aﬀord pure product 3b as an orange powder (0.05 g, 0.04 mmol, 83%).
1H NMR (DMSO, 400 MHz): δ 9.63 (m, 2 H, NH DFO), 9.08 (s, 1
H, NHC(O)Ar), 7.97 (m, 4 H, ArH), 7.78 (m, 6 H, Ar H), 7.65 (m, 2
H, NOH DFO), 7.46 (m, 6 H, ArH), 5.36 (d, J = 6.4 Hz, 2 H, ArH p-
cymene), 5.29 (d, J = 6.2 Hz, 2 H, ArH p-cymene), 3.71 (m, 2 H, CH2
DFO), 3.45 (m, 6 H, CH2 DFO), 3.38 (t, J = 7.0 Hz, residual Et2O),
2.98 (m, 5 H, CH2 DFO and CH(CH3)2), 2.76 (m, 2 H, CH2 DFO),
2.56 (t, J = 6.8 Hz, 4 H, CH2 DFO), 2.31 (residual mesylate), 2.27 (t, J
= 6.5 Hz, 4 H, CH2), 1.96 (m, 3 H, CH3C(O) DFO), 1.78 (s, 3 H,
ArCH3), 1.60−1.16 (m, 24 H), 1.09 (t, J = 7.0 Hz, residual Et2O), 0.95
(dd, J = 6.9, 3.5 Hz, 6 H, iPr). 13C{1H} NMR (DMSO, 101 MHz): δ
172.0 (2 C, C hydroxamic acid DFO), 171.3 (2 C, C amide DFO),
170.6 (1 C, C(O)NDFO), 170.1 (1 C, C hydroxamic acid DFO), 134.6
(d, 1J = 37.0 Hz, 2 C, P-C(Ar)), 134.1 (d, J = 9.3 Hz, C(Ar)), 133.6 (d,
1J = 29.0 Hz, 1 C, P-C(Ar)), 130.6 (1C, C(O)C(Ar)), 128.2 (d, J = 9.8
Hz, C(Ar)), 128.1 (d, J = 9.8 Hz, CAr), 119.3 (2C, C(Ar)), 95.9 (1 C,
ArCCH3), 95.8 (1 C, ArCCH2), 89.3 (d, J = 4.0 Hz, CH arene), 87.0
(d, J = 6.0 Hz, CH arene), 86.0 (CH arene), 85.5 (CH arene), 64.9
(residual Et2O), 47.1 (DFO), 46.8 (DFO), 38.8, 38.4 (DFO), 29.8
(DFO), 28.8 (DFO), 27.6 (DFO), 26.6, 26.0 (DFO), 23.5 (DFO),
22.9, 21.3 (2 C, iPr), 20.4 (DFO). 17.4 (1 C, ArCH3), 15.2 (residual
Et2O).
31P NMR (DMSO, 162 MHz): δ 31P NMR (162 MHz,
DMSO) δ 26.0, 25.4, 25.2, 24.0. HRMS (ESI/Q-TOF) m/z: [M −
H]+ calcd for C54H74N6O9PRu 1083.4314, found 1083.4325.
Compound 3c. According to the general procedure, ligand 2c (0.06
g, 0.07 mmol, 1.0 equiv) and dichloro(p- cymene)ruthenium dimer
(0.02 g, 0.07 mmol, 1.0 equiv) reacted in methanol (10 mL) for 1 h.
After completion, diethyl ether (30 mL) was added, and the orange
precipitate was washed several times with diethyl ether to aﬀord pure
product 3c as a yellow powder (0.06 g, 0.04 mmol, 82%). 1H NMR
(DMSO, 400 MHz): δ 9.71 (m, 3 H, NH), 9.48 (d, J = 5.7 Hz, 1 H,
ArH), 9.38 (d, J = 6.0 Hz, 1 H, ArH), 8.64 (s, 1 H, ArH), 8.51 (m, 1 H,
ArH), 8.00 (t, J = 5.3 Hz, 1 H, NOH), 7.80 (s, 2 H, NOH), 7.72 (d, J
= 5.5 Hz, 1 H, ArH), 7.65 (t, J = 6.0 Hz, 1 H, ArH), 6.21 (t, J = 5.4 Hz,
2 H, ArH p-cymene), 5.96 (t, J = 7.0 Hz, 2 H, ArH p-cymene), 5.40 (s,
2 H, CO2CH2Ar), 3.45 (t, J = 7.0 Hz, 6 H, CH2), 3.38 (t, J = 7.0 Hz,
residual Et2O), 2.99 (q, J = 6.6 Hz, 6 H, CH2), 2.73−2.66 (m, 2 H,
CH2), 2.62−2.55 (m, 8 H, CH2), 2.31 (residual mesylate), 2.27 (t, J =
7.4 Hz, 4 H, CH2), 2.17 (s, 3 H, ArCH3), 1.96 (s, 3 H, CH3CO),
1.53−1.18 (m, 21 H, CH2 and ArCH3), 1.09 (t, J = 7.0 Hz, residual
Et2O), 0.94 (dt, J = 5.0, 2.4 Hz, 6 H, iPr).
13C{1H} NMR (DMSO, 101
MHz): δ 172.4 (1 C, C(O)NDFO), 172.0 (2 C, hydroxamic acid DFO),
171.3 (2 C, C amide DFO), 170.8 (1 C, CO2CH2Ar), 170.1 (1 C, C
hydroxamic acid DFO), 155.4 (1 C, Ar), 155.0 (1 C, Ar), 154.5 (1 C,
Ar), 153.8 (1 C, Ar), 152.0 (1 C, Ar), 150.4 (1 C, Ar), 128.4 (1 C, Ar),
124.7 (1 C, Ar), 124.5 (1 C, Ar), 120.4 (1 C, Ar), 103.4 (2 C, Ar p-
cymene), 86.6 (1 C, Ar p-cymene), 86.4 (1 C, Ar p-cymene), 83.8 (1
C, Ar p-cymene), 83.7 (1 C, Ar p-cymene), 64.9 (residual Et2O), 62.9
(1 C, ArCH2), 47.1 (DFO), 46.8 (DFO), 38.4 (DFO), 30.4 (1 C,
CH2CONDFO), 29.9 (DFO), 29.6 (1 C, CH2CO2CH2), 29.0 (1 C,
CH2CO2CH2), 28.8 (DFO), 27.6 (DFO), 26.0 (DFO), 23.5 (DFO),
21.7 (2 C, iPr), 20.7 (1 C, ArCH3 bpy), 20.4 (DFO), 18.3 (1 C,
ArCH3 arene), 15.2 (residual Et2O). HRMS (ESI/Q-TOF) m/z: [M]
+
calcd for C51H76ClN8O11Ru 1113.4376, found 1113.4366.
Compound 3d. According to a reported procedure,55 [Ru(μ-
oxalato)(3-(4-methylcyclohexa-1,4-dien-1-yl)propionic acid) (PTA)]
(0.08 g, 0.15 mmol, 1.0 equiv) was stirred in DMSO (2 mL) with
TBTU (0.05 g, 0.15 mmol, 1.0 equiv) and DIPEA (0.14 mL, 0.75
mmol, 5.0 equiv) for 30 min. Then a solution of deferoxamine
mesylate (0.10 g, 0.15 mmol, 1.0 equiv) in DMSO (1 mL) was added
dropwise, and the reaction was monitored by MS. After 10 min, the
reaction was deemed complete, acetone (40 mL) was added, and the
precipitate was ﬁltered, washed twice with acetone, and dried in vacuo
to aﬀord pure product 3d as a yellow powder (0.11 g, 0.10 mmol,
70%). 1H NMR (CDCl3, 400 MHz): δ 9.64 (m, 3H, NH DFO), 7.86
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(t, J = 5.5 Hz, 1 H, NOH DFO), 7.77 (t, J = 5.6 Hz, 2 H, NOH DFO),
5.90 (d, J = 6.0 Hz, 2H, ArH p-cymene), 5.83 (d, J = 6.0 Hz, 2 H, ArH
p-cymene), 4.45 (m, 6 H, NCH2P PTA), 4.03 (s, 6 H, NCH2N PTA),
3.45 (t, J = 6.8 Hz, 6 H, CH2 DFO), 3.16 (s, 2 H, CH2), 2.99 (q, J =
6.6 Hz, 6 H, CH2 DFO), 2.57 (t, J = 7.2 Hz, 4 H, CH2), 2.41 (m, 4 H,
ArCH2CH2), 2.26 (t, J = 7.2 Hz, 4 H, CH2 DFO), 2.08 (residual
acetone), 1.96 (s, 3 H, CH3CO DFO), 1.94 (s, 3 H, ArCH3), 1.55−
1.13 (m, 18 H, CH2 DFO).
13C{1H} NMR (DMSO, 101 MHz): δ
172.0 (2 C, hydroxamic acid DFO), 171.3 (2 C, C amide DFO), 170.4
(1 C, C(O)NDFO), 170.1 (1 C, C hydroxamic acid DFO), 164.5 (2 C,
oxalate), 95.6 (1 C, ArCCH3), 95.5 (1 C, ArCCH2), 88.4 (d, 2 C, J =
3.3 Hz, ArC), 87.2 (d, 2 C, J = 3.7 Hz, ArC), 71.8 (d, J = 7.3 Hz, 3 C,
PTA), 49.8 (d, J = 14.2 Hz, 3 C, PTA), 47.1 (DFO), 46.8 (DFO), 38.4
(DFO), 35.0 (1 C, CH2), 29.9 (1 C, CH2), 29.9 (DFO), 28.8 (DFO),
27.6 (DFO), 26.0 (DFO), 23.5 (DFO), 20.4 (DFO), 17.7 (1 C,
ArCH3).
31P NMR (DMSO, 162 MHz): δ −33.33. HRMS (ESI/Q-
TOF) m/z: [M − Na]+ calcd for C43H70N9O13RuNa 1076.3784, found
1076.3815.
General Procedure for the Synthesis of Bimetallic Iron and
Ruthenium Complexes Fe-3a/b. To a methanolic solution of
complex 3a/b (1.0 equiv), a methanolic solution of FeCl3 (74 mM, 1.0
equiv) was added. A color change was observed from yellow/orange to
red. The solvent was removed by evaporation, and the Fe-3a/b
product was dried in vacuo.
Compound Fe-3a. According to the general procedure, complex 3a
(0.01 g, 0.01 mmol, 1.0 equiv) was converted to bimetallic complex
Fe-3a (0.01 g, 0.01 mmol, quantitative). HRMS (ESI/Q-TOF) m/z:
[M − H]+ Calcd for C42H65N7O9Cl2RuFe 1039.2614; Found
1039.2619.
Compound Fe-3b. According to the general procedure, complex 3b
(0.01 g, 0.01 mmol, 1.0 equiv) was converted to bimetallic complex
Fe-3b (0.01 g, 0.01 mmol, quantitative). HRMS (ESI/Q-TOF) m/z:
[M − H]+ calcd for C54H72N6O9PCl2RuFeNa 1230.2766, found
1230.2772.
Discrepancies in the elemental analysis values were found to be
higher than the acceptable 0.4% range and are therefore not reported.
Similar observations have been made for other DFO conjugates
reported in the literature.70 This is due to the high coordination ability
of the siderophore that apparently collects metal ions during
measurements. NMR and MS data indicate good purity of all
compounds.
Stability Studies. The stability of complexes 3a−d and their
iron(III) derivatives in pseudocell culture conditions was assessed in
aqueous 100 mM NaCl and 5% DMSO for 72 h at 298 K and
monitored via 1H and 31P NMR when possible, and ESI-MS(+)
otherwise.
Cell Culture and in Vitro Antiproliferative Activity. The
human ovarian carcinoma (A2780) cell line was obtained from the
European Collection of Cell Cultures. The human embryonic kidney
(HEK-293) cell line was obtained from ATCC (Sigma, Buchs,
Switzerland). Penicillin streptomycin, RPMI 1640 GlutaMAX (where
RPMI = Roswell Park Memorial Institute), and DMEM GlutaMAX
media (where DMEM = Dulbecco’s modiﬁed Eagle medium) were
obtained from Life Technologies, and fetal bovine serum (FBS) was
obtained from Sigma. The cells were cultured in RPMI 1640
GlutaMAX (A2780) and DMEM GlutaMAX (HEK-293) media
containing 10% heat-inactivated FBS and 1% penicillin streptomycin
at 37 °C and CO2 (5%). The cytotoxicity was determined using the 3-
(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide
(MTT) assay.57 Cells were seeded in ﬂat-bottomed 96-well plates as
a suspension in a prepared medium (100 μL aliquots and
approximately 4300 cells/well) and preincubated for 24 h. Stock
solutions of compounds were prepared in DMSO and were rapidly
diluted in a medium. The solutions were sequentially diluted to give a
ﬁnal DMSO concentration of 0.5% and a ﬁnal compound
concentration range (0−200 μM). Cisplatin was tested as a positive
control (0−10 μM). RAPTA-C was tested as a negative control (200
μM). The compounds were added to the preincubated 96-well plates
in 100 μL aliquots, and the plates were incubated for 72 h. MTT (20
μL, 5 mg/mL in Dulbecco’s phosphate buﬀered saline) was added to
the cells, and the plates were incubated for a further 4 h. The culture
medium was aspirated, and the purple formazan crystals, formed by
the mitochondrial dehydrogenase activity of vital cells, were dissolved
in DMSO (100 μL/well). The absorbance of the resulting solutions,
directly proportional to the number of surviving cells, was quantiﬁed at
590 nm using a microplate reader. The percentage of surviving cells
was calculated from the absorbance of wells corresponding to the
untreated control cells. The reported IC50 values (Table 1) are based
on the means from three independent experiments, each comprising
four tests per concentration level.
Antibacterial Assay. All bacteria were cultured in Cation-adjusted
Mueller Hinton broth (CAMHB) at 37 °C overnight. A sample of
each culture was then diluted 40-fold in fresh broth and incubated at
37 °C for 1.5−3 h. The resultant mid-log phase cultures were diluted
(CFU/mL measured by OD600) and then added to each well of the
compound containing plates, giving a cell density of 5 × 105 CFU/mL
and a total volume of 50 μL. All of the plates were covered and
incubated at 37 °C for 18 h without shaking. Inhibition of bacterial
growth was determined measuring absorbance at 600 nm (OD600)
using a Tecan M1000 Pro monochromator plate reader. The
percentage of growth inhibition was calculated for each well using
the negative control (media only) and positive control (bacteria
without inhibitors) on the same plate as references. The signiﬁcance of
the inhibition values was determined by modiﬁed Z-scores, calculated
using the median and MAD of the samples (no controls) on the same
plate. Samples with inhibition value above 80% and Z-Score above 2.5
for either replicate (n = 2 on diﬀerent plates) were classed as actives.
Samples with inhibition values between 50−80% and Z-Score above
2.5 for either replicate (n = 2 on diﬀerent plates) were classed as
partial actives. Colistin and vancomycin were used as positive bacterial
inhibitor standards for Gram-negative and Gram-positive bacteria,
respectively. The antibiotics were provided in four concentrations,
with two above and two below its MIC value, and plated into the ﬁrst
8 wells of column 23 of the 384-well NBS plates. The quality control
(QC) of the assays was determined by the antimicrobial controls and
the Z′-factor (using positive and negative controls). Each plate was
deemed to fulﬁll the quality criteria (pass QC), if the Z′-factor was
above 0.4, and the antimicrobial standards showed full range of
activity, with full growth inhibition at their highest concentration, and
no growth inhibition at their lowest concentration.
Antifungal Assay. Fungi strains were cultured for 3 days on yeast
extract−peptone dextrose (YPD) agar at 30 °C. A yeast suspension of
1 × 106 to 5 × 106 CFU/mL (as determined by OD530) was prepared
from ﬁve colonies. The suspension was subsequently diluted and
added to each well of the compound-containing plates giving a ﬁnal
cell density of fungi suspension of 2.5 × 103 CFU/mL and a total
volume of 50 μL. All plates were covered and incubated at 35 °C for
24 h without shaking. Growth inhibition of C. albicans was determined
by measuring absorbance at 530 nm (OD530), while the growth
inhibition of C. neoformans was determined measuring the diﬀerence in
absorbance between 600 and 570 nm (OD600−570), after the addition of
resazurin (0.001% ﬁnal concentration) and incubation at 35 °C for
additional 2 h. The absorbance was measured using a Biotek Synergy
HTX plate reader. The percentage of growth inhibition was calculated
for each well, using the negative control (media only) and positive
control (fungi without inhibitors) on the same plate. The signiﬁcance
of the inhibition values was determined by modiﬁed Z-scores,
calculated using the median and MAD of the samples (no controls)
on the same plate. Samples with inhibition value above 80% and Z-
Score above 2.5 for either replicate (n = 2 on diﬀerent plates) were
classed as actives. Samples with inhibition values between 50−80% and
Z-score above 2.5 for either replicate (n = 2 on diﬀerent plates) were
classed as partial actives. Fluconazole was used as a positive fungal
inhibitor standard for C. albicans and C. neoformans.
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